Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Idarubicin hydrochloride [USAN:USP:INN]
RN: 57852-57-0
UNII: 5VV3MDU5IE
InChIKey: JVHPTYWUBOQMBP-RVFAQHLVSA-N

Note

  • An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Molecular Formula

  • C26-H27-N-O9.Cl-H

Molecular Weight

  • 533.9582
 

Classification Codes

  • Antineoplastic
  • Drug / Therapeutic Agent
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Idarubicin hydrochloride [USAN:USP:INN]

Synonyms

  • (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside, hydrochloride
  • 4-Demethoxydaunorubicin hydrochloride
  • 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis)-
  • EINECS 260-990-7
  • Idamycin
  • Idamycin PFS
  • Idarubicin HCl
  • Idarubicin hydrochloride
  • Idarubicin hydrochloride PFS
  • IMI 30
  • NSC 256439
  • UNII-5VV3MDU5IE
  • Zavedos

Systematic Names

  • (7S-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride
  • 5,12-Naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxyhydrochloride, (7S-cis)-
  • Daunomycin, 4-demethoxy-, hydrochloride

Superlist Name

  • Idarubicin hydrochloride

Registry Numbers

CAS Registry Number

  • 57852-57-0

FDA UNII

  • 5VV3MDU5IE

Related Registry Number

  • 58957-92-9 (Parent)

System Generated Number

  • 0057852570

Molecular Formulas

Molecular Formula

  • C26-H27-N-O9.Cl-H

Molecular Formula Fragments

  • C26-H27-N-O9
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

1S/C26H27NO9.ClH/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31;/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3;1H/t10-,15-,16-,17-,21+,26-;/m0./s1

InChIKey

JVHPTYWUBOQMBP-RVFAQHLVSA-N

Smiles

Cl.C[C@@H]1O[C@H](C[C@H](N)[C@@H]1O)O[C@H]2C[C@@](O)(Cc3c(O)c4C(=O)c5ccccc5C(=O)c4c(O)c23)C(=O)C

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD intravenous > 500ug/kg (0.5mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995.
mouse LD50 intravenous 4100ug/kg (4.1mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995.
mouse LD50 oral 13980ug/kg (13.98mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995.
mouse LD50 subcutaneous 4690ug/kg (4.69mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995.
mouse LDLo intraperitoneal 700ug/kg (0.7mg/kg)   Cancer Treatment Reports. Vol. 60, Pg. 829, 1976.
rat LD50 intravenous 3080ug/kg (3.08mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995.
rat LD50 oral 5430ug/kg (5.43mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995.
rat LD50 subcutaneous 2930ug/kg (2.93mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 364, 1995.